previous page  Report Home next page

Overview compounds Audited by KPMG

Status of our innovative compounds

[ XLS ]

1

Developed in cooperation with ImClone: Erbitux® is a trademark of ImClone Systems Inc.

2

Exclusive worldwide licensing rights acquired from Oncothyreon Inc.

3

Collaboration with Takeda Pharmaceutical Company Ltd.

4

Inlicensed from Idera Pharmaceuticals Inc.

5

Collaboration with Micromet AG

6

Collaboration with Rigel Pharmaceuticals Inc.

7

Collaboration with ZymoGenetics Inc.

8

All rights acquired from Santhera Pharmaceuticals AG

9

Collaboration with Newron Pharmaceuticals S.p.A.

10

Collaboration with AstraZeneca UK Limited

11

Collaboration with BioMarin Pharmaceuticals, Inc.

12

Collaboration withAmbrx, Inc.

13

Collaboration with NovImmune S.A.

14

Inlicensed from ZymoGenetics Inc.

 

EGFR: Epidermal Growth Factor Receptor

EpCAM: Epithelial Cell Adhesion Molecule

GD2: Cancer-associated ganglioside

MUC: Mucinous glycoprotein that is abnormally expressed in various cancers

SCCHN: Squamous cell carcinoma of the head and neck

NSCLC: Non-small-cell lung cancer

SCLC: Small-cell lung cancer

OI/ART: Ovulation Induction / Assisted Reproductive Technology

HARS: HIV-associated Adipose Redistribution Syndrome

 

 

 

 

Therapeutic area

Compound

Indication

Status

Oncology

Erbitux ® (cetuximab)1

Colorectal cancer, 1st line therapy; EMEA: filed

Filed

 

 

Adjuvant colorectal cancer

Phase III

 

 

SCCHN

Phase III

 

 

NSCLC

Phase III

 

 

Gastric cancer

Phase III

 

Stimuvax ®2

MUC1-expressing tumors: NSCLC

Phase III

 

Cilengitide

Glioblastoma

Phase III

 

Erbitux ® (cetuximab)1

Breast cancer

Phase II

 

Matuzumab (EMD 72000)3

EGFR-expressing tumors: NSCLC

Phase II

 

 

EGFR-expressing tumors: gastric cancer

Phase II

 

Tucotuzumab celmoleukin
(EMD 273066/huKS-IL2)

EpCAM-expressing tumors: ovarian cancer

Phase II

 

 

EpCAM-expressing tumors: SCLC

Phase II

 

EMD 273063 (hu14.18-IL2)

GD2-expressing tumors: melanoma

Phase II

 

 

GD2-expressing tumors: Pediatric neuroblastoma

Phase II

 

IMO-20554

Renal cell carcinoma

Phase II

 

Adecatumumab (MT201)5

EpCAM-expressing tumors

Phase I

 

Aurora kinase inhibitor
(AS703569)6

Solid tumors and hematological malignancies

Phase I

 

Atacicept7

Hematological malignancies

Phase I

 

NHS-IL2-LT (EMD 521873)

Solid tumors

Phase I

 

DI17E6 (EMD 525797)

Solid tumors

Phase I

 

Eg 5 inhibitor (EMD 534085)

Solid tumors and hematological malignancies

Phase I

 

Survivac (cancer vaccine)

Solid tumors

Phase I

 

MEK inhibitor (AS703026)8

Solid tumors

Phase I

 

IMO-20554

Solid tumors

Phase I

Neurode-
generative
Diseases

New formulation of Rebif ®

Relapsing forms of multiple sclerosis (MS)
EMEA: approved; FDA: filed

Filed

 

Clinically isolated syndrome

Phase III

Cladribine tablets

Relapsing forms of MS

Phase III

Safinamide9

Early-stage Parkinson’s disease

Phase III

 

Mid- to late-stage Parkinson’s disease

Phase III

Atacicept7

MS

Phase II

Fertility

Anastrozole10

OI and improvement of follicular development

Phase II

 

Hyperglycosylated FSH

Infertility (OI / ART)

Phase II

Endocrinology

Recombinant growth hormone

HARS: in discussion with the FDA

Phase III

 

Sapropterin11

Hyperphenylalaninemia; EMEA: filed

Filed

 

ARX 20112

Growth hormone deficiencies

Phase I/II

Autoimmune &
Inflammatory Diseases

Atacicept7

Systemic lupus erythematosus

Phase II/III

 

Rheumatoid arthritis

Phase II

Anti-CD 3 (NI-0401)13

Crohn‘s disease / Renal transplantation

Phase I

Fibroblast growth factor 1814

Osteoarthritis

Phase I

Other products

EMD 387008

Type 2 diabetes

Phase II

 

FC EPO

Anemia associated with chronic renal failure

Phase I
top
Last update 18.02.2008, © Merck KGaA, Darmstadt, Germany

Search this report

Services

More on other websites

Sustain| Change | Grow – Link to coverstory (teaser)